AstraZeneca's oncology sales jump 18% in second-quarter 2025, fueled by key drugs and new launches like Truqap and Datroway.

With its domination of the indication- and brand-specific analyses, it should come as no surprise that AstraZeneca led the ...

AstraZeneca (AZN) announced Enhertu in combination with pertuzumab has been granted Breakthrough Therapy Designation in the U.S. for the first-line treatment of adult patients with unresectable or ...

Despite its potential, incorporating new treatments like T-DXd into a first-line setting faces several barriers, explains Michael Hassett, MD, MPH, chief quality officer at Dana-Farber Cancer ...

Britain’s cash-strapped Labour government cannot fold to every corporate lobbying campaign. But it ought to heed Soriot and ...

Boehringer's Hernexeos is now FDA-approved for patients with HER2-positive NSCLC, bringing it into direct competition with ADC Enhertu.

Antibody-drug conjugates are currently being investigated in more than 260 clinical trials.“It’s going to be the next novel ...

AstraZeneca has built its leading presence in the pharma and biotech industry on patent-protected drugs and a developing pipeline that support a wide moat. The strong replenishment of new drugs ...

Boehringer Ingelheim GmbH won approval in the U.S. for its drug to treat a challenging form of lung cancer, offering a growth ...